Description
Indication & Scope
Xeligekimab Injection treats moderate to severe plaque psoriasis in adults eligible for systemic therapy or phototherapy
- Mechanism: Fully human monoclonal antibody binds and neutralizes IL-17A and IL-17F, blocks inflammatory signaling that causes psoriatic skin lesions.
- Drug class: IL-17 inhibitor, fully human monoclonal antibody, dermatological biologic agent.
- Clinical use: Induction and long-term maintenance therapy for plaque psoriasis.
| Generic Name | Xeligekimab Injection |
| Brand Name | JinLiXi |
| Ingredient | Xeligekimab Injection |
| Dosage Form | Injection |
| Package | 1ml: 100mg*1 syringe/box |
| Conditions Treated | Moderate to severe plaque psoriasis |
| Taboos | 1. Active serious infectious diseases such as active tuberculosis, sepsis
2. Severe anaphylactic hypersensitivity to the active ingredient or formulation excipients 3. Patients with untreated chronic infections 4. Severe immunodeficiency patients |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Refrigerate at 2°C ~ 8°C, do not freeze, avoid direct sunlight and high temperature |
| Manufacturer | ZhiXiangJinTai Biopharmaceutical Co., Ltd |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20240036 |
| Approval Date | Aug 20, 2024 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Loading doses at Week 0, Week 2, followed by maintenance dose every 4 weeks.
Time: Fixed long-term dosing intervals for continuous disease control.
Instructions for use: Subcutaneous injection into abdomen, thigh or upper outer arm.
Interaction: Reduced efficacy of live vaccines; combined use with systemic immunosuppressants increases infection risk.
Side effects: Nasopharyngitis, upper respiratory tract infection, injection site erythema and pain, headache, mild candidiasis.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
Which disease is Xeligekimab Injection mainly used to treat?
It is applied for adult patients with moderate to severe plaque psoriasis who need systemic therapy or phototherapy.
What is the pharmacological classification of Xeligekimab Injection?
It is a fully human monoclonal antibody and a selective IL-17A/IL-17F inhibitor belonging to dermatological biologic agents.
What infections should patients avoid when using Xeligekimab Injection?
Patients with active severe infections such as tuberculosis and sepsis are contraindicated to receive Xeligekimab treatment.
What are the typical mild side effects of Xeligekimab Injection?
Common side effects include nasopharyngitis, upper respiratory tract infections, injection site erythema, headache and mild fungal infections.
JinLiXi® | Xeligekimab Injection | Plaque Psoriasis | DengYueRX
INN: Xeligekimab Injection
Indications: Treatment of moderate to severe plaque psoriasis
Dosage Form: Injection
Strength: 1ml: 100mg/syringe
